Procept BioRobotics launches AquaBeam trial in France

This article was originally published here
Share

Procept BioRoboticsProcept BioRobotics said today that it launched a clinical trial aimed at winning reimbursement approval in France for its AquaBeam prostate treatment.

Redwood Shores, Calif.-based Procept said the 30-patient Francais Water study is designed to evaluate the safety and effectiveness of prostate ablation via waterjet in treating benign prostate hyperplasia in men aged 45 to 80. The primary outcome is total change in International Prostate Symptom score at 6 months, with a final data collection slated for August 2018, according to ClinicalTrials.gov.

Get the full story at our sister site, The Robot Report.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply